Tuberculosis among HIV-infected patients receiving HAART: Long term incidence and risk factors in a South African cohort

AIDS

Volumn 19, Issue 18, 2005, Pages 2109-2116

  Lawn, Stephen D ^a,b,c   Badri, Motasim ^a   Wood, Robin ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Africa; Antiretroviral treatment; HAART; HIV; Tuberculosis

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CELL COUNT; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; GENDER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HOSPITAL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNE DEFICIENCY; IMMUNE RESPONSE; INCIDENCE; INFECTION RISK; LOWEST INCOME GROUP; MALE; MICROBIOLOGICAL EXAMINATION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SOCIOECONOMICS; SOUTH AFRICA; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE; TUBERCULOSIS; VIRUS LOAD; WORLD HEALTH ORGANIZATION;

EID: 27944451480     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000194808.20035.c1     Document Type: Article

References (34)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860.
2. Brodt HR, Kamps BS, Gute P, Knupp B, Staszewski S, Helm EB. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS 1997; 11:1731-1738.
3. Hogg RS, Heath KV, Yip B, Craib KJ, O'Shaughnessy MV, Schechter MT, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998; 279:450-454.
4. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-129.
5. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997; 277:112-116.
6. Carcelain G, Debre P, Autran B. Reconstitution of CD4+ T lymphocytes in HIV-infected individuals following antiretroviral therapy. Curr Opin Immunol 2001; 13:483-488.
7. Kirk O, Reiss P, Uberti-Foppa C, Bickel M, Gerstoft J, Pradier C, et al. Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. Ann Intern Med 2002; 137:239-250.
8. Ledergerber B, Mocroft A, Reiss P, Furrer H, Kirk O, Bickel M, et al. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups. N Engl J Med 2001; 344:168-174.
9. Mussini C, Pezzotti P, Miro JM, Martinez E, de Quiros JC, Cinque P, et al. Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study. Clin Infect Dis 2004; 38:565-571.
10. Currier JS, Williams PL, Koletar SL, Cohn SE, Murphy RL, Heald AE, et al. Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4 cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team. Ann Intern Med 2000; 133:493-503.
11. Kirk O, Gatell JM, Mocroft A, Pedersen C, Proenca R, Brettle RP, et al. Infections with Mycobacterium tuberculosis and Mycobacterium avium among HIV-infected patients after the introduction of highly active antiretroviral therapy. EuroSIDA Study Group JD. Am J Respir Crit Care Med 2000; 162:865-872.
12. Ledergerber B, Egger M, Erard V, Weber R, Hirschel B, Furrer H, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA 1999; 282:2220-2226.
13. Girardi E, Antonucci G, Vanacore P, Libanore M, Errante I, Matteelli A, et al. Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection. AIDS 2000; 14:1985-1991.
14. Jones JL, Hanson DL, Dworkin MS, de Cock KM. HIV-associated tuberculosis in the era of highly active antiretroviral therapy. The Adult/Adolescent Spectrum of HIV Disease Group. Int J Tuberc Lung Dis 2000; 4:1026-1031.
15. Santoro-Lopes G, de Pinho AM, Harrison LH, Schechter M. Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy. Clin Infect Dis 2002; 34:543-546.
16. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002; 359:2059-2064.
17. Seyler C, Toure S, Messou E, Bonard D, Gabillard D, Anglaret X. Risk factors for active tuberculosis after antiretroviral treatment initiation in Abidjan. Am J Respir Crit Care Med 2005; 172:123-127.
18. Girardi E, Antonucci G, Vanacore P, Palmieri F, Matteelli A, Lemoli E, et al. Tuberculosis in HIV-infected persons in the context of wide availability of highly active antiretroviral therapy. Eur Respir J 2004; 24:11-17.
19. Lawn SD, Bekker LG, Wood R. How effectively does HAART restore immune responses to Mycobacterium tuberculosis? Implications for tuberculosis control. AIDS 2005; 19:1113-1124.
20. Williams BG, Dye C. Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS. Science 2003; 301:1535-1537.
21. Harries AD, Hargreaves NJ, Kemp J, Jindani A, Enarson DA, Maher D, et al. Deaths from tuberculosis in sub-Saharan African countries with a high prevalence of HIV-1. Lancet 2001; 357:1519-1523.
22. de Cock KM, Chaisson RE. Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection. Int J Tuberc Lung Dis 1999; 3:457-465.
23. World Health Organization. Strategic Framework to Decrease the Burden of TB/HIV. [Document WHO/CDS/TB/2002.296, WHO/HIV_AIDS/2002.2. 2002.] Geneva: World Health Organization, 2004.
24. Badri M, Bekker LG, Orrell C, Pitt J, Cilliers F, Wood R. Initiating highly active antiretroviral therapy in sub-Saharan Africa: an assessment of the revised World Health Organization scaling-up guidelines. AIDS 2004; 18:1159-1168.
25. Lange CG, Valdez H, Medvik K, Asaad R, Lederman MM. CD4+ T-lymphocyte nadir and the effect of highly active antiretroviral therapy on phenotypic and functional immune restoration in HIV-1 infection. Clin Immunol 2002; 102:154-161.
26. Lange CG, Lederman MM, Medvik K, Asaad R, Wild M, Kalayjian R, et al. Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection. AIDS 2003; 17:2015-2023.
27. Lawn SD, Badri M, Wood R. Risk factors for tuberculosis among HIV-infected patients receiving antiretroviral treatment. Am J Respir Crit Care Med 2005; in press.
28. Wood R, Maartens G, Lombard CJ. Risk factors for developing tuberculosis in HIV-1-infected adults from communities with a low or very high incidence of tuberculosis. J Acquir Immune Defic Syndr 2000; 23:75-80.
29. Hsieh SM, Hung CC, Pan SC, Wang JT, Tsai HC, Chen MY, et al. Restoration of cellular immunity against tuberculosis in patients coinfected with HIV-1 and tuberculosis with effective antiretroviral therapy: assessment by determination of CD69 expression on T cells after tuberculin stimulation. J Acquir Immune Defic Syndr 2000; 25:212-220.
30. World Health Organization. Scaling up Antiretroviral Therapy in Resource-limited Settings: Guidelines for a Public Health Approach; Executive Summary. Geneva: World Health Organization 2002. Accessed 15 April 2005: http://www.who.int/hiv/pub/prev-care/en/WHO_ARV_Guidelines.pdf.
31. Morris L, Martin DJ, Bredell H, Nyoka SN, Sacks L, Pendle S, et al. Human immunodeficiency virus-1 RNA levels and CD4 lymphocyte counts, during treatment for active tuberculosis in South African patients. J Infect Dis 2003; 187:1967-1971.
32. Piketty C, Castiel P, Belec L, Batisse D, Si MA, Gilquin J, et al. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease. AIDS 1998; 12:745-750.
33. Lederman HM, Williams PL, Wu JW, Evans TG, Cohn SE, McCutchan JA, et al. Incomplete immune reconstitution after initiation of highly active antiretroviral therapy in human immunodeficiency virus-infected patients with severe CD4+ cell depletion. J Infect Dis 2003; 188:1794-1803.
34. Dean GL, Edwards SG, Ives NJ, Matthews G, Fox EF, Navaratne L, et al. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS 2002; 16:75-83.